Viking stock falls after Roche’s obesity data (NASDAQ:VKTX)

Bathroom scale, measuring tape and space for text on white wooden floor, top view. Weight loss concept

Liudmila Chernetska/iStock via Getty Images

Update 2.37 PM EST: Adds details on Raymond James upgrade

Viking Therapeutics (NASDAQ:VKTX) was a notable decliner among anti-obesity drug developers on Thursday after Swiss pharma giant Roche (OTCQX:RHHBY) said its dual GLP-1/GIP receptor agonist, CT-388, caused roughly 19% averageloss in a Phase 1 trial.

#Viking #stock #falls #Roches #obesity #data #NASDAQVKTX

Leave a Reply

Your email address will not be published. Required fields are marked *